Literature DB >> 2133060

Oxidative stress, disturbance of energy balance, and death of ascites tumour cells under menadione (vitamin K3) action.

V L Gabai1, A S Seilanov, A F Mosin.   

Abstract

Resting ascites tumour cells (Ehrlich and EL-4 thymoma) treated with menadione (50 microM) died (up to 80% cell death over 2 h) without dividing (i.e. interphase). Glucose (25 mM) added to the cell suspensions partially protected these cells from menadione action. During incubation of the cells with menadione, the rates of free oxidation and lipid peroxidation were elevated, cellular ATP and nonprotein SH-group levels were much decreased, and [Ca2+]i was moderately increased. From a comparison of these effects and cell survival rates with those seen with rotenone, KCN (both inhibitors of oxidative phosphorylation), and H2O2 (an inducer of oxidative stress), it is concluded that ATP depletion is the main factor leading to the death of cells treated with menadione. The level of cellular ATP dropped to less than 10% of its initial value after 1 h incubation with menadione and may have resulted in irreversible damage to cytoskeletal structures, bleb formation, and changes in plasma membrane permeability that are incompatible with cell viability.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2133060

Source DB:  PubMed          Journal:  Biomed Sci


  2 in total

1.  Serum markers variation consistent with autoschizis induced by ascorbic acid-menadione in patients with prostate cancer.

Authors:  Eduardo Lasalvia-Prisco; Silvia Cucchi; Jesús Vázquez; Eduardo Lasalvia-Galante; Wilson Golomar; William Gordon
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

2.  Menadione triggers cell death through ROS-dependent mechanisms involving PARP activation without requiring apoptosis.

Authors:  Gabriel Loor; Jyothisri Kondapalli; Jacqueline M Schriewer; Navdeep S Chandel; Terry L Vanden Hoek; Paul T Schumacker
Journal:  Free Radic Biol Med       Date:  2010-10-27       Impact factor: 7.376

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.